(IN BRIEF) AstraZeneca's Tagrisso (osimertinib) demonstrates significant improvement in progression-free survival (PFS) for patients with unresectable, Stage III EGFR-mutated non-small…
(IN BRIEF) AstraZeneca's Tagrisso receives FDA approval for treating adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung…
Phase III FLAURA trial results show Tagrisso reduced the risk of progression or death by more than half, with consistent…